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Background: Most interventions for depression have shown small or no effects. ‘Third wave‘ cognitive therapy and
mentalization-based therapy have both gained some ground as treatments of psychological problems. No
randomised trial has compared the effects of these two interventions for patients with major depression.
Methods/ design: We plan a randomised, parallel group, assessor-blinded superiority clinical trial. During two years
we will include 84 consecutive adult participants diagnosed with major depressive disorder. The participants will be
randomised to either ‘third wave‘ cognitive therapy versus mentalization-based therapy. The primary outcome will
be the Hamilton Rating Scale for Depression at cessation of treatment at 18 weeks. Secondary outcomes will be the
proportion of patients with remission, Symptom Checklist 90 Revised, Beck’s Depression Inventory, and The World
Health Organisation-Five Well-being Index 1999.
Discussion: Interventions for depression have until now shown relatively small effects. Our trial results will provide
knowledge about the effects of two modern psychotherapeutic interventions.
Trial registration: ClinicalTrials: NCT01070134Background
Depression
According to the WHO, major depressive disorder is the
second largest healthcare problem worldwide in terms of
disability caused by illness [1]. It afflicts an estimated
17% of individuals during their lifetimes at tremendous
cost to the individual and society [2,3]. Roughly a third
of all depressive disorders take a chronic course [4,5].
Approximately 15% of depressive patients will commit
suicide over a 10 to 20 year period [6].Antidepressants
Antidepressant medication remains the mainstay in the
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reproduction in any medium, provided the orhave shown that most antidepressants presumably only
obtain a beneficial effect in severely depressed patients,
and even this effect seems to be clinically small [8,9]. As
the therapeutic benefits of antidepressants seem to be
limited there is an urgent need to identify effective inter-
ventions for depression.
‘Third wave’ cognitive therapy
Cognitive therapy is one of the most well-known and
used psychotherapeutic techniques. Aaron T. Beck ori-
ginally developed cognitive therapy for depression [10].
Beck believed that critical life events could accentuate
hidden negative beliefs, which could generate negative
automatic thoughts [10]. These negative thoughts could
lead to symptoms of depression, which then could
reinforce more negative automatic thoughts [10]. The
main goal of the original ‘cognitive model of depression’
is to correct these negative beliefs and thoughts in order
to treat the depressive symptoms [10]. One review has
questioned if this focus on changing thoughts is an ef-
fective element of the cognitive therapy [11]. Oural Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that classic cognitive therapy versus ‘no intervention’
might be an effective intervention for major depressive
disorder. However, the effects of cognitive therapy seem
relatively small [12].
During the last two decades modern forms of cogni-
tive therapy have been developed. These techniques are
often classified as ‘third wave’ cognitive therapies, in-
cluding dialectical behaviour therapy (DBT), acceptance
and commitment therapy (ACT), schema therapy,
mindfulness-based cognitive therapy (MBCT), and meta-
cognitive therapy (MCT) [13]. These therapies have
drawn great attention throughout the world, and espe-
cially mindfulness has been implemented in numerous
different contexts in recent years [14-16]. One system-
atic review has found that ‘third wave’ cognitive ther-
apy might prevent relapse of depression [17], and
preliminary trials indicate that ‘third wave’ cognitive
therapy versus ‘no intervention’ or ‘treatment as usual’
is effective for acutely depressed patients [18,19]. ‘Third
wave’ cognitive therapies might also be effective inter-
ventions for other psychological problems [13,15,20,21].
One trial has shown comparable effects between cogni-
tive therapy and ‘third wave cognitive therapy in non-
melancholic depression, but the trial only included
45 participants [22]. Even though evidence is lacking, it
seems theoretically possible that the treatment ele-
ments of ‘third wave’ cognitive therapy might be more
effective than classic cognitive therapy for depressed
patients [23]. We have chosen ‘third wave’ cognitive
therapy as our experimental intervention because it is
practically feasible for us to conduct a trial with this
intervention.
Mentalization-based therapy
In some health-care systems psychodynamic therapy is
the most commonly used form of psychotherapy [24].
Mentalization-based therapy is a psychodynamic treat-
ment rooted in attachment and personality theory [25].
It aims to strengthen patients’ capacity to understand
their own and others’ mental states in attachment
contexts in order to address their difficulties with affect,
impulse regulation, and interpersonal functioning [25,26].
Mentalization-based therapy was originally developed to
treat borderline personality disorder [27] but is now used
to treat a variety of different psychiatric disorders such as
depression, eating disorders, substance abuse, and other
types of personality disorders [25,26].
Our systematic review of randomised clinical trials has
shown that psychodynamic therapy versus ‘no interven-
tion’ might be an effective intervention for major depres-
sive disorder [28], but the effects of mentalization-based
therapy versus ‘no intervention’ for major depressive dis-
order has not been examined in randomised trials [28].We have chosen mentalization-based therapy as our
control intervention because it is practically feasible for
us to conduct a trial with this intervention.
‘Third wave’ cognitive therapy versus mentalization-
based therapy
No randomised clinical trials or systematic reviews
have been conducted examining the effects of ‘third
wave’ cognitive therapy versus mentalization-based
therapy [29].
Design & methods
We will randomise 84 consecutive patients with major
depressive disorder 1:1 to one of two interventions:
1. ‘Third wave’ cognitive therapy, approximately n=42.
2. Mentalization-based therapy, approximately n=42.
The inclusion phase is expected to run for about two
years.
Inclusion
Patients will be referred from general practitioners, prac-
ticing specialist physicians, medical departments, and
psychiatric departments. Referrals may be denied, either
by virtue of the referral papers or via a physician inter-
view. All trial participants will be on sick leave due to
psychological illness. To participate in the trial the par-
ticipant must meet all of the inclusion criteria and none
of the exclusion criteria. No special announcement of
the project will be made to referrers, so the participants
will be similar to patients normally referred to a psychi-
atric outpatient clinic.
The referrals will be discussed at the patient confer-
ence, and relevant patients will be offered a preliminary
consultation (collection of master data, which can be
used by the therapists during the course of treatment)
and a subsequent medical consultation. During the
medical consultation relevant patients will be informed
of and offered participation in the trial. If the patient
agrees to participate in the trial, an appointment will be
made for completion of relevant questionnaires. If the
patient is included according to the inclusion and ex-
clusion criteria, he or she will be randomised to either
‘third wave’ cognitive therapy versus mentalization-
based therapy.
Inclusion criteria
1. Age from 18 to 65 years.
2. Major depressive disorder (SCID I) [30].
3. Beck’s Depression Inventory (BDI II) > 13 [31].
4. Written informed consent.
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1. Current psychosis, diagnosis of schizophrenia, or
schizotypal personality disorder (DSM IV-TR) [32].
2. A significant alcohol or substance abuse (assessed
during the preliminary consultations).
3. Initiated or changed medical anti-depressive
treatment less than six weeks before randomisation.
4. Pregnancy.
5. No written informed consent.
We have chosen not to include participants over 65
years. This is due to the risk of dementia, which may
affect treatment effects. We have chosen BDI > 13 as
one of the inclusion criteria to be sure that included
participants have significant subjective depressive symp-
toms. Participants with psychosis, schizophrenia, schizo-
typal personality disorder, pregnancy, alcohol abuse, and
substance abuse are excluded because these groups of
participants are traditionally assessed in separate trials.
Interventions
Common to both treatment groups
The intensive treatments will last 18 weeks for each par-
ticipant. The groups will be ‘slow-open’ (new patients
enter the group continually) and will contain a max-
imum of seven patients. After 18 weeks of intensive
treatment every participant will be treated with a follow-
up intervention with weekly 1.5-hour sessions of group
therapy.
All participants will be offered a communal breakfast
twice a week, and group psycho-education for one hour
a week. Discussion of treatment plans will be offered
after four weeks and after 12 weeks of treatment. The
lead clinical consultant, who is not otherwise involved in
the trial, will shortly after inclusion offer a consultation
regarding psychopharmacological treatment of the psy-
chological problems. The lead clinical consultant will be
free to choose any relevant medicine. After the first con-
sultation, medical consultations will be offered by de-
mand of the participant. During the course of treatment,
all trial participants with children will be offered partici-
pation in a parent support group (four weekly one-hour
sessions).
In the absence of one of the therapists (illness, holi-
days, courses, etc.) the individual therapy will be can-
celled. The group therapy will continue, to the extent
that this is possible. When participants cancel or do not
attend, they will not get compensatory sessions.
‘Third wave’ cognitive therapy
Traditional cognitive therapy seeks, in general, to iden-
tify irrational thoughts and to ‘correct’ these thoughts
[10]. ‘Third wave’ cognitive therapy, and so forthmindfulness (see introduction), is more focused on
awareness and acceptance of negative feelings. Our
cognitive intervention is primarily based on the pri-
nciples from mindfulness, so we have chosen to classify
this cognitive intervention as ‘third wave’ cognitive ther-
apy [13].
The ‘third wave’ cognitive therapy treatment consists
of a weekly individual session (45-50 min.) together with
weekly mindfulness-skills training group (1.5 hours).
The weekly individual session includes
- Introduction of the cognitive model and mindfulness.
- Identification of thoughts, feelings, behaviour, and
physical sensations.
- Work on acceptance of feelings and life
circumstances.
- Work on assumptions.
- Stress reduction.
- Behavioural experiments and acceptance of difficult
feelings.
- Self esteem training.
- Mindfulness training.
- Tools to prevent relapse.
The weekly mindfulness-skills training group includes
Skills training with teaching of the four basic mindfulness
skills ‘FALB’ (training in Focusing, Acceptance, Labelling
techniques, Body awareness) together with self-esteem
training and mindful communication. The skills training
group will run in a continuous cycle of six sessions. Con-
sequently, participants go through the skills training
group’s program three times during the course of the in-
tensive treatment.
For details, please see the manual ‘Third wave’ cogni-
tive therapy - a treatment manual’ for a detailed descrip-
tion of the cognitive intervention [33].
Mentalization-based therapy
The mentalization-based therapy treatment consists of a
weekly individual session (45-50 min.), together with
weekly group therapy (1.5 hours).
Mentalising means to understand what lies behind
thoughts and activities (e.g., mental states, wishes, needs,
goals, and other feelings) [25], and is an active process
working both consciously and unconsciously [25]. Men-
talization is the process by which we make sense of each
other and ourselves. The focus of the mentalization-
based therapy is on improving the patient’s ability to
mentalise — he or she is trained to mentalise.
Initial task in mentalization-based therapy
The initial task in mentalization-based therapy is to help
the patient to see and learn that her reactions are
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understood as a result of what happens in relation to
others. Furthermore, the patient is trained in realising
that it is not obvious what other people think and feel,
and consequently other people cannot know what the
patient thinks and feels.
The five steps in mentalization-based therapy
Mentalization-based therapy has five steps that are
repeated a number of times during an intervention
period. The first step is validation of the patient’s current
affect — empathising and supporting the patient. This is
followed by clarification of the situation and an ela-
boration on the patient’s feelings and thoughts; what
triggered the feeling; etc. The fourth step is ‘basic menta-
lization’. The patient’s feelings are related to the actual
circumstances including other people’s reactions, feelings,
wishes etc. The final step is to work with interpretation
and the transference, including transference interpreta-
tions. It is important every step is worked through before
going to the next step.
In the first part of an intervention period most time is
spend working on step 1-3. Later in an intervention
period most time will be spend on step 3-5.
Therapeutic stance
The therapist must try to demonstrate a ‘mentalising
attitude’. The therapist’s attitude must be validating, ‘not-
knowing’, and curious questioning the patient about
feelings and thoughts. The focus must be on feelings
and interpersonal relations. It is of great importance
that the therapist identifies when the patient is ‘not-
mentalising’, and that the therapist intervenes when this
happens. The therapist must assist the patient in regulat-
ing the level of the emotions so the patient is able to
mentalise; with very strong emotions the patient will not
be able to realise what lies behind thoughts and activ-
ities, i.e., to mentalise. The therapist must remember not
to overestimate the patient’s ability to mentalise, which
is a common pitfall. The therapist must help the patient
get different perspectives on life events, conflicts, etc.
In mentalization-based therapy the work with the
transference process is different from the ordinary psy-
chodynamic way [34]. In mentalization-based therapy it
is called ‘mentalising the transference’. ‘Mentalising the
transference’ means engaging the patient in reflecting on
the relation to the therapist and on the therapist’s mind
in the here-and-now. This helps the patient to have ideas
of how others se her, by talking about it with the
therapist and hearing the therapist’s perspective. In
mentalization-based therapy transference is not under-
stood as a repetition of earlier ways of relations, and
interpretations based on unconscious processes are not
part of the therapy. The counter-transference ismanaged by the therapists by explicitly telling the pa-
tient about the feelings and thoughts the therapeutic
process arouse in the therapist. The therapist will always
try to present another view and perspective to the pa-
tient. In mentalization-based therapy the focus is con-
stantly on ‘mentalising’ interpersonal relations including
the relation here-and-now between the patient and the
therapist [25,35].
Please see ‘Treatment manual for MBT’ for further
details [36].
Therapists
Each intervention group will have two therapists. The
‘third wave’ cognitive therapy and the mentalization-
based therapy therapists will have comparable psycho-
therapeutic education and experience.
‘Third wave’ cognitive therapy therapists
1. The principal clinical investigator (M.D.) is a specialist
in general medicine. He has over 10 years of experience
in cognitive behavioural therapy and mindfulness and is
an approved specialist and supervisor in cognitive behav-
ioural therapy (Danish Psychiatric Association).
2. An occupational therapist with seven years of ex-
perience in cognitive behavioural therapy.
Mentalization-based therapy therapists
1. A mentalization-based therapy licensed psychiatrist
with over 20 years of experience with psychodynamic
therapy and mentalization-based therapy.
2. A nurse with seven years of experience with
psychodynamic therapy and mentalization-based
therapy.
Adherence to treatment manual
All individual sessions will be recorded on an audio re-
corder and all group sessions will be recorded on video.
During the trial an independent research assistant will rate
4 × 10 of the recordings (10 sessions each of: ‘third wave’
cognitive therapy individual therapy, mentalization-based
individual therapy, ‘third wave’ cognitive therapy group
therapy, and mentalization-based group therapy) to check
compliance with the manual. This is done using a check-
list and the assessor rates the degree of adherence to the
manuals 0-5 (0=no adherence; 5=very high adherence).
Assessments
Before randomisation: Hamilton Rating Scale for De-
pression (HDRS) [37], Symptom Checklist 90 Revised
(SCL 90-R) [38], Beck’s Depression Inventory (BDI II)
[31], World Health Organisation-Five Well-being Index
1999 (WHO 5) [39], Structured Clinical Interviews for
DSM-IV Disorders (the depression section of SCID I
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Personality Pathology-Basic Questionnaire (DAPP-BQ)
[41], use of medication, age sex, marital status, and edu-
cation level.
After 9 weeks of intervention: BDI II WHO 5, use of
medication, suicide attempts, and suicides during the
intervention period.
After 18 weeks of intervention (end of intensive treat-
ment): HDRS, BDI II, WHO 5, SCL 90-R, use of medica-
tion, suicide attempts, and suicides during the intervention
period.
After 26 weeks of follow-up treatment: HDRS, SCL
90-R, DAPP-BQ, BDI II, WHO 5, suicide attempts, and
suicides during the intervention period.
Outcome measure hierarchy
Primary outcome measure
- HDRS (after 18 weeks of treatment).
Secondary outcome measures
- SCL-90-R (GSI- score after 18 weeks of treatment).
- The proportion of patients who achieve remission
(after 18 weeks of treatment). We have, pragmatically,
chosen to define remission as HDRS below 8 [42].
- BDI II (after 18 weeks of treatment).
- WHO 5 (after 18 weeks of treatment).
Other outcome measures
- Adverse events. We will classify adverse events as
serious or non-serious. Serious adverse events are
defined as any medical occurrence that is life
threatening, results in death, or persistent or significant
disability, or any medical event, which might jeopardise
the patient, or require intervention to prevent it [43].
All other adverse events (that is, any medical
occurrence not necessarily having a causal relationship
with the treatment, but did, however, cause
discontinuation of the treatment) are considered as
non-serious.
- Scores on HDRS, BDI, SCL 90-R, WHO 5 after 26
weeks of treatment.
- DAPP-BQ.
Description of the outcome assessment instruments
HDRS
The severity of a depression can be assessed using the
Hamilton Rating Scale for Depression (HDRS) [37]. It is
the most commonly used assessment scale for depressive
symptoms [8,44,45]. It is a continuous, observer-based
assessment method and involves 17 items. Using this
scale, the degree of depression is assessed (13 to 17points = mild depression; 18 to 28 points, = moderate
depression; over 28 points = severe depression).
SCL 90-R
Symptom Checklist 90 Revised (SCL 90-R) [38] is one of
the most commonly used instruments for evaluating
psychological and psychopathological symptoms. SCL
90-R is a self-reported questionnaire with 90 items. Each
item assesses the degree (0-4) of a symptom during the
previous week. Global Severity Index (GSI) derived from
the questionnaire is designed to measure overall psycho-
logical distress.
BDI II
Beck’s Depression Inventory (BDI II) [31]. BDI is self-
reported questionnaire with 21 items. The BDI score
can be interpreted as: 10–18 mild-moderate depression;
19–29 moderate-severe depression; and 30–63 severe
depression.
WHO 5
World Health Organisation-Five Well-being Index 1999
(WHO 5) [39] is a self-reported questionnaire that
attempts to assess the trial participant’s satisfaction and
‘quality of life’. The questionnaire consists of five items
and results in a score between 0 and 100.
DAPP-BQ
Personality disorder traits can assessed using the Dimen-
sional Assessment of Personality Pathology-Basic Question-
naire (DAPP-BQ) [41]. It is a self-reported questionnaire
involving 290 items and 18 scales.
SCID
The Structured Clinical Interviews for DSM-IV Disor-
ders (SCID) is an observer-based diagnostic interview
used to determine DSM-IV Axis I disorders (major men-
tal disorders, SCID 1) and Axis II disorders (personality
disorders, SCID 2) [30,40].
Reliability tests for assessment
Two experienced psychologists will perform the Hamil-
ton interviews. During the trial period about 20 of the
Hamilton interviews will be rated by both interviewers
and the correlation will be presented.
The two members of staff who perform the SCID II
interviews will rate five SCID interviews before the trial
period begins, and the correlation will be presented.
Data-management
All data will be stored in the principal investigator’s
office and at the Copenhagen Trial Unit. All data will be
anonymised on conclusion of the project, i.e., after pub-
lication of all results. Privacy of trial participants are
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Personal Data and the Health Act. The project has been
notified to the Danish Data Protection Agency.
All completed HDRS interviews, BDI II, and SCL
90 are sent directly to the Copenhagen Trial Unit
for data-management.
Randomisation
The randomisation will be performed by the Copen-
hagen Trial Unit. A computer will generate a non-
stratified randomisation sequence that will be unknown
to the investigators. The randomisation sequence will be
generated using a block size unknown to the investiga-
tors. A research assistant will randomise by calling the
Copenhagen Trial Unit providing a personal pin code
and patient number.
Blinding
The Hamilton psychologist interviewer will be blinded
to the treatment allocation and will be instructed to
avoid questions beside the Hamilton interview. All inter-
viewees will be instructed not to mention which treat-
ment they have been allocated to. Therefore, the HDRS
has been chosen as the primary outcome. It is not pos-
sible to blind neither the therapists nor the participants
to treatment allocation. A blinded statistician at The Co-
penhagen Trial Unit will perform statistical analyses with
the two intervention groups coded as ‘A’ and ‘B’.
The lead clinical consultant performing the medical
consultations will not be blinded to treatment allocation.
All information given to the participants before filling
in every questionnaire will be the same for every partici-
pant and will be standardised.
Sample size
With a ‘minimal relevant mean difference’ (MIREDIF)
between the two compared interventions of 5 HDRS
points, an alpha of 0.05 (type I error), a power of 0.90
(type II error of 10%), and a standard deviation (SD) = 7,
the sample size calculation shows that a total of 84 parti-
cipants are necessary. The calculation is performed using
the program “Power and sample size calculations”, ver-
sion 2.1.31.
Statistical analyses
The primary analyses will be intention-to-treat (ITT)
analyses. Per protocol analyses may also be considered.
Continuous outcomes will be compared between the
two intervention groups using the univariate general lin-
ear model. If the model assumptions cannot be fulfilled
with reasonable approximation a non-parametric test will
be used (Mann Whitney). The analysis will be repeated
using the baseline variable as a co-variate and the results
will be discussed in case of major discrepancies betweenthe two results. Binary outcomes will be compared be-
tween the groups using logistic regression. The outcomes
will be divided into two classes comprising the primary
outcome and all the secondary ones respectively. Dmi-
trienko et al’s gatekeeping testing procedure with parallel
inferences will be used to control the family-wise error
rate [46]. All raw P values of all outcome comparisons
between the two groups will be presented.
As explorative analyses, all of the above analyses will
be repeated with the indicator of comorbid personality
disorder as well as the interaction between this indicator
and the intervention indicator included. If P of the inter-
action is ≤ 0.05, an analysis of the corresponding sub-
groups of patients will be conducted.
If more than 5% of the primary outcome measure is
missing, multiple imputation will be used (SPSS version
18 or later). If so, the imputation result will be consid-
ered the primary result. This analysis will be supplemen-
ted by the following sensitivity analysis. Let A be the
group where a beneficial significant effect was observed
and B the other group. Missing values in group A will
be imputed by the mean value of group B and missing
values in group B will be imputed by the mean value of
group A. The resulting two distributions will probably
not be normal and the variances rather small. So the
resulting distributions will be compared using a non-
parametric test (Mann-Whitney). This test result will be
contrasted to that obtained by comparing the two
groups without imputed values also using the non-
parametric test.
Prevention of missing values
The primary investigator will ensure that all question-
naires will be completed and will be present at the loca-
tion where the participant assessments take place. The
primary investigator and a research secretary will inde-
pendently check if all participants have been rated at the
relevant time points.
All participants will, in good time, be invited in written
letter to participate in the assessments. If the trial parti-
cipants do not show up or cancel, they will be invited to
another assessment. In such circumstances the trial par-
ticipants will be invited at least three times to a given as-
sessment, and will be contacted on phone or by mail. A
research secretary (Anita Jensen) will try to solve any
problem that hinders the participant in showing up to
the assessment.
Ethical considerations and regulatory approval
There are no immediate ethical problems regarding this
trial. Research has not identified any significant adverse
effects or risks from either of the compared interventions —
and we do not know which is the best intervention. Dur-
ing the trial period any adverse event will be reported.
Jakobsen et al. BMC Psychiatry 2012, 12:232 Page 7 of 9
http://www.biomedcentral.com/1471-244X/12/232The trial has obtained approval by the Regional Ethics
Committee of Zealand (no: SJ-43), and is registered at the
Danish Data Protection Agency (no: 2008-58-0020).
Participants will be informed of the trial in writing and
verbally, and written informed consent will be obtained
from every participant before inclusion. All trial partici-
pants may, on request, be permitted access to further in-
formation about the project. The individual therapists
and the principal investigator will perform this function.
No expense allowance is offered to trial participants.
Discussion
Our protocol has a number of strengths. First, a trial
protocol was registered before randomisation began
(ClinicalTrials.gov; no.: NCT01070134). In this protocol
the outcome hierarchy and analyses plans were pre-
sented and these are published in this present publica-
tion. Secondly, the trial protocol has been developed
according to good clinical research practice enabling the
randomised trial to be conducted with low risk of bias
and a high degree of external validity [47-50]. Thirdly,
the participants in this trial will be similar to patients
normally referred to a psychiatric outpatient clinic, and
clinicians can therefore more easily relate the results
from this trial to a given clinical context. Fourthly, both
interventions will be conducted using manuals and ad-
herence to the treatment manuals will be tested. This
makes it possible to implement the interventions in clin-
ical practice, and the two interventions can be assessed
in future trials. Moreover, we have used the most com-
monly used outcome measure in trials assessing the
effects of psychotherapeutic interventions for depression
(HDRS) [28,37,44,51], as well as other clinically relevant
outcome measures (e.g., quality of life, suicide attempts,
suicides). The two treatments uses about the same
resources, so economical considerations seem less im-
portant in the choice between the two.
Our trial protocol has a number of limitations. Due to
practical circumstances we have planned to include a
limited number of trial participants. This will evidently
increase the risk of random errors (‘play of chance’). In
calculating our sample size we have used a ‘minimal
relevant mean difference’ (MIREDIF) of five HDRS
points between the two interventions. Former systematic
reviews have shown much less differences in effects sizes
between compared interventions for depression [44,51,52].
It could be argued that we have set our presumed MIRE-
DIF unrealistically high. However, as experienced Hamilton
interviewers we believe that five HDRS points is a reason-
able MIREDIF between the two interventions. A smaller
mean difference between two interventions will have lim-
ited clinical relevance.
We have chosen to classify our control intervention as
‘mentalization-based therapy’. This intervention was, asmentioned, originally designed to treat borderline per-
sonality disorder but is now used in a number of differ-
ent clinical settings symptoms [25,26]. As we except
about 80% of the participants will have comorbidity of
depression and personality disorder [53], we believe that
mentalization-based therapy will be a relevant control
intervention. Mentalization-based therapy is a relatively
new intervention and we did not identify any relevant
treatment manual we could use. We chose to create our
own treatment manual, but due to limited resources the
mentalization-based manual became relatively short.
The content of the control intervention is therefore less
strictly defined and this is a further limitation of this
trial.
After the initial 18 weeks of intervention, both inter-
vention groups will be offered a follow-up intervention
(1 weekly group session). This follow-up intervention
will due to limited resources not be manualised and ad-
herence to treatment manual will not be assessed. The
results from the follow-up intervention will be difficult
to interpret because the form and content of the both
follow-up interventions will be unclear. Furthermore,
since the participants will be free to leave the trial after
the 18 weeks of intensive treatment (before the follow-
up treatment begins), it might be unclear if a certain
group of patients will be systematically excluded from
the analysis and this might cause biased long-term fol-
low-up results. The participants are free to leave the trial
at any time point but based on our experience, we ex-
pect a relatively large number of participants to be lost
to follow up after the 18 weeks of intensive treatment.
Interventions for depression have until now shown
relatively small effect sizes. We want to examine two
modern psychotherapeutic methods — and we hope that
the results from this trial can contribute to new know-
ledge about effective interventions for depression.
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